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Background. The eye is an excellent candidate for gene therapy as it is immune privileged and much of the disease-causing
genetics are well understood. Towards this goal, we evaluated the efficiency of compacted DNA nanoparticles as a system for
non-viral gene transfer to ocular tissues. The compacted DNA nanoparticles examined here have been shown to be safe and
effective in a human clinical trial, have no theoretical limitation on plasmid size, do not provoke immune responses, and can be
highly concentrated. Methods and Findings. Here we show that these nanoparticles can be targeted to different tissues
within the eye by varying the site of injection. Almost all cell types of the eye were capable of transfection by the nanoparticle
and produced robust levels of gene expression that were dose-dependent. Most impressively, subretinal delivery of these
nanoparticles transfected nearly all of the photoreceptor population and produced expression levels almost equal to that of
rod opsin, the highest expressed gene in the retina. Conclusions. As no deleterious effects on retinal function were observed,
this treatment strategy appears to be clinically viable and provides a highly efficient non-viral technology to safely deliver and
express nucleic acids in the retina and other ocular tissues.
Citation: Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI (2006) Efficient Non-Viral Ocular Gene Transfer with Compacted DNA
Nanoparticles. PLoS ONE 1(1): e38. doi:10.1371/journal.pone.0000038
INTRODUCTION
The eye is comprised of several specialized tissues that work
together to initiate visual perception in response to photons of
light. Any insult to these tissues results in a consequence to vision
and an impact on the quality of life for the patient. Both
environmental trauma and genetic disorders can cause varying
degrees of ocular diseases. Current therapies for ocular disorders
are often surgically-based or topical treatments however they often
fail to correct the underlying genetic deficit. As the eye is easily
accessible and immune-privileged, the use of gene transfer is an
attractive therapeutic option for numerous forms of blinding
disorders.
Many disease-causing mutations and their contribution to the
pathogenesis of ocular diseases including cataracts, glaucoma, and
retinitis pigmentosa have been well characterized [1–5]. In
addition, several treatment strategies for overcoming these genetic
deficits have been attempted and proven in tissue culture and
various animal models [6–10]. Many attempts to rescue genetic
deficits with viral gene therapy have proven effective in the eye
[11–15]. Perhaps the most encouraging trial has occurred in
Briard dogs harboring a naturally occurring mutation in the
RPE65 gene, which causes visual impairment similar to Early
Onset Severe Retinal Dystrophy in humans [16,17]. Bennett and
colleagues used adeno-associated virus to express the RPE65
cDNA which restored retinal function and has successfully
persisted over 3 years [18–20]. Although viral vectors also have
been successful in alleviating hereditary retinal degeneration in
mice [12,21], they can be limited by cell tropism, the size of the
expression cassette to be transferred, and host immunity to repeat
infections [22,23]. Additionally, concerns regarding the safety of
using viral vectors in human patients have been raised and some
trials have resulted in oncogenesis or even mortality [22,24–26].
Towards the mission of the NIH roadmap for nanomedicine
and to identify a complementary approach for gene transfer, we
examined the feasibility of using compacted DNA nanoparticles as
an efficacious platform for non-viral gene transfer to the eye.
These nanoparticles consist of a neutrally-charged complex
containing a single molecule of plasmid DNA compacted with
polyethylene glycol (PEG)-substituted lysine peptides [27]. These
complexes are stable in saline and serum, can efficiently transfect
post-mitotic airway cells following in vivo delivery, are non-toxic
following lung delivery, and can be repetitively dosed without
decrement in biologic activity [27–29]. The size of the expression
cassette does not appear to be a limiting factor as plasmids up to
20 kbp have demonstrated cellular transfection and gene transfer
[30]. Varying the counterion at the time of compaction can lead to
different 3-dimensional shapes of the nanoparticles which can
facilitate the development of customized nanoparticles to transfect
a multitude of cell types [31]. Clinical studies also have
demonstrated the safety and effectiveness of this system in human
subjects [32]. In this study, we demonstrate that the use of
compacted DNA nanoparticles is an effective and robust platform
for gene transfer to various tissues of the eye. Varying the site of
injection and type of nanoparticle resulted in cell-specific trans-
fection. Furthermore, altering the dose of the injected nanopar-
ticles can allow fine-tuning to the correct level of gene expression
needed for the therapeutic gene. This gene delivery approach
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pZEEGFP5.1 (5,147 bp) encodes the enhanced green fluorescent
protein cDNA transcriptionally-controlled by the CMV immedi-
ate-early promoter and enhancer, as previously described [33].
Nanoparticle Formulation
DNA nanoparticles were formulated by mixing plasmid DNA with
CK30PEG10K, a 30-mer lysine peptide with an N-terminal
cysteine that is conjugated via a maleimide linkage to 10 kDa
polyethylene glycol, as previously described [29]. Nanoparticles
were concentrated up to 4 mg/ml of DNA in saline.
Mice
All experiments and animal maintenance were approved by the
local Institutional Animal Care and Use Committee (Oklahoma
City, OK, U.S.A.) and conformed to the guidelines on the care
and use of animals adopted by the Society for Neuroscience and
the Association for Research in Vision and Ophthalmology
(Rockville, MD, U.S.A.). Balb/cJ mice were obtained from
Jackson Labs (www.jax.org) and used for all experiments.
Quantitative RT-PCR
qRT-PCR was performed as previously described [34]. Briefly,
total RNA was extracted from the tissue of a single eye using
Trizol reagent (Invitrogen Inc.) and then DNAse treated with
RNAse-free-DNAse I (Promega Inc.). Incubation of 5 U DNAse/ug
RNA was carried out at 37u for 1hr, as these excessive conditions
were needed to eliminate any isolated nanoparticles that could
skew downstream qRT-PCR analyses. Reaction cleanup was
performed using an RNeasy mini kit (Qiagen Inc.). Reverse
transcription was performed using an oligo-dT primer and
Superscript III reverse transcriptase (Invitrogen Inc.). To ensure
the complete removal of nanoparticles, PCR was performed on all
cDNA samples using primers (CMV-F1/CMV-R1) to amplify
a region of the CMV promoter as this region would only be
amplified due to the presence of contaminating nanoparticle or
plasmid DNA. Amplification was only detected in positive control
samples of pure nanoparticle DNA, demonstrating sufficient
removal of nanoparticle contamination from isolated RNA
samples. qRT-PCR was performed in triplicate on each cDNA
sample using an iCycler (Bio-Rad Inc.) and DcT values were
calculated against the neuronal housekeeping gene hypoxanthine
phosphoribosyltransferase (Hprt). Hprt was assigned an arbitrary
expression level of 10,000 and relative gene expression values were
calculated by the following calculation: Relative Expression
=10,000/2
DcT, where DcT=(Gene cT2Hprt cT). This was
repeated with 4 independent samples for each experimental group
and the mean expression value is presented with the standard
deviation. Agarose gel electrophoresis and disassociation curve
analysis were performed on all PCR products to confirm
proper amplification. Primer sequences were: HPRT-F:
GCAAACTTTGCTTTCCCTGGTT; HPRT-R: CAAGGGCA-
TATCCAACAACA; CMV-F1: AACGCCAATAGGGACTT-
TCC; CMV-R1: TATCCACGCCCATTGATGTA; EGFP-F:
CACATGAAGCAGCACGACTT; EGFP-R: AGTTCACCTT-
GATGCCGTTC; RHO-F: TCACCACCACCCTCTACACA;







Tissue fixation and sectioning were performed as previously
described [35]. Briefly, eyes from mice at 2-days post-injection
were enucleated and fixed in 4% paraformaldehyde/PBS for
16 hr at 4uC prior to embedding in OCT media and subsequent
freezing of the block. Tissue sections (10 mm thickness) were cut
with a microtome and vectashield with DAPI (Vector Laboratories
Inc.) was applied prior to coverslipping. Sections were viewed at
room temperature with an Axioskop 50 (Carl Zeiss Inc.) in the
autoexpose mode using a 620, 640, or 663 objective. Images
were captured with an Axiocam HR digital camera (Carl Zeiss Inc.)
using Axiovision 3.1 software (Carl Zeiss Inc.). Panels labeled
‘‘FITC’’ represent images captured of native GFP fluorescence in
the 500–60 nm wavelength when cryosections were subjected to
excitation at 485 nm.
Immunohistochemistry
Tissue fixation and sectioning were performed as previously
described [34]. Briefly, eyes from mice at 2 days post-injection
were enucleated and fixed in 4% paraformaldehyde/PBS for 16 h
4uC prior to paraffin embedding. Tissue sections (10 mm thickness)
were deparaffinized, rehydrated, and blocked in 5% BSA/PBS for
30 min at room temperature (RT). Slides were briefly washed with
PBS and incubated with anti-GFP (Molecular Probes Inc.) at
1:1000 in 16BSA/PBS for 2 h at RT. Following a brief washing
in PBS, vectashield with DAPI (Vector Laboratories Inc.) was applied
and the slide was coverslipped. Sections were viewed at room
temperature with an Axioskop 50 (Carl Zeiss Inc.) in the autoexpose
mode using a 620, 640, or 663 objective. Images were captured
with an Axiocam HR digital camera (Carl Zeiss Inc.) using
Axiovision 3.1 software (Carl Zeiss Inc.).
Electroretinography
Subretinal injection of 1 mL Saline (0.9%), naked plasmid (0.6 mg),
AC-GFP (0.6 mg), or TFA-GFP (0.6 mg) was performed. At 7 days
post-injection, ERG analyses were performed as previously
described [34]. For the assessment of scotopic response, a stimulus
intensity of 1.89 log cd s m
22 was presented to the dark-adapted,
dilated eyes in a Ganzfeld (model GS-2000; Nicolet). To evaluate
photopic response, animals were light adapted for 5 minutes under
a light source of 1.46 log cd m
22 intensity, and a strobe flash was
presented to the dilated eyes in the Ganzfeld with a stimulus
intensity of 1.89 log cd s m
22. Significance was determined using
one-way analysis of variance (ANOVA) and post-hoc tests using
Bonferroni’s pair-wise comparisons (Prism, ver. 3.02; GraphPad,
San Diego, CA).
Electron Microscopy
Electron micrographs were prepared using carbon-coated electron
microscope grids (Ted Pella) and counterstained with uranyl
acetate, as previously described [33].
RESULTS
To determine the utility of these nanoparticles in ocular gene
therapy, we conducted a set of proof-of-principle experiments
using a plasmid to express enhanced green fluorescent protein
(EGFP) driven by the cytomegalovirus (CMV) promoter
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ticle formulations generated by the presence of either acetate (AC)
or trifluoroacetate (TFA) as the lysine amine counterion at the
time of DNA compaction. The TFA particles are ellipsoids and
short rods while the AC particles form longer rod-like structures
(Fig 1). In both cases, the minor diameter of each particle is less
than the 25 nm nuclear membrane pore, facilitating uptake into
the nucleus [29]. Furthermore, to target different ocular tissues, we
varied the site of ocular injection between the intravitreal space
and subretinal space as we hypothesized that the area of delivery
may cause different cell types to express EGFP. For every mouse,
only one eye was injected while the contra-lateral eye was mock-
injected to serve as a control.
Intravitreal injections of 1 mL of 0.6 mg/mL AC-GFP, TFA-
GFP, or naked plasmid DNA were performed in adult Balb/c
mice and evaluated by quantitative RT-PCR (qRT-PCR) for
EGFP expression at 2 days post-injection. Following euthanasia,
the lens and retina were individually separated from the retinal
pigment epithelium, choroid, and sclera (PECS). Expression
analysis demonstrated that both the AC-GFP and TFA-GFP
nanoparticles were capable of promoting high levels of EGFP
expression in the lens after intravitreal injection (Fig 2). Substantial
expression of EGFP was also detected in the PECS and retina
following intravitreal injection, albeit at levels multi-fold lower
than that observed in the lens. Delivery of the naked plasmid
generated minimal levels of EGFP expression and no expression
was detected in the mock injected samples.
To determine which cells were transfected after intravitreal
injection, direct fluorescence microscopy was performed on ocular
cryosections at 2-days post injection. The mock- and naked
plasmid-injected eyes showed fluorescence in the FITC channel
throughout the outer segment (OS) layer of the retina (Fig 3a).
This observation is common in the FITC channel of retinal
cryosections as the photoreceptor OSs are packed tightly with the
opsin protein which causes this natural autofluorescence [36–38].
No other fluorescent signal was observed in the mock- or naked
plasmid-injected eyes except in the OS. Examination of the eyes
injected with TFA-GFP and AC-GFP nanoparticles showed
a fluorescent signal in the inner plexiform layer for TFA-GFP
and in retinal ganglion cells (RGCs) for both particles (Fig 3b).
Substantial EGFP fluorescence was also detected in the lens,
cornea, and trabecular meshwork (Fig 3c), consistent with the
qRT-PCR findings.
To target nanoparticle driven expression of EGFP in the
photoreceptors and RPE, we delivered 1 mL of AC-GFP, TFA-
GFP, or naked plasmid to the retina by a subretinal injection. Our
laboratory has previously demonstrated this method is capable of
delivering material to over 90% of the photoreceptor cells [39].
After 2-days post-injection, ocular tissues were isolated as
described above and examined for EGFP mRNA expression by
qRT-PCR (Fig 4). Subretinal injection of AC-GFP and TFA-GFP
was extremely effective in producing EGFP expression in the
PECS and retina. Levels of EGFP after AC-GFP delivery were 2-
fold higher in the PECS and 1.5-fold higher in the retina.
Expression of EGFP after subretinal injection of naked plasmid
was minimal or completely absent in the mock-injected controls.
Surprisingly, EGFP expression was detected in the lens after
subretinal injection of AC-GFP but only nominal levels were
achieved with injection of TFA-GFP. This finding may also be
indicative of the amount of reflux into the vitreous during the
subretinal injection procedure as the standard deviation associated
with this measurement is quite high.
Direct fluorescence microscopy was performed on cryosectioned
eyes after 2-days post-injection to localize expression throughout
the retina. As in the intravitreal samples, retinal autofluorescence
was detected throughout the OS layer in both mock and naked
plasmid injected samples (Fig 5a). Eyes injected with AC-GFP
displayed EGFP expression throughout the outer nuclear layer
(ONL), indicative of the uptake and expression of the nanopar-
ticle-delivered plasmid to the photoreceptors. These sections also
showed nominal levels of EGFP fluorescence in the RPE and
choroid. The TFA-GFP nanoparticles appeared to confer sub-
stantial levels of EGFP expression throughout the RPE and sparse
expression in the ONL. In several cryosections of eyes subretinally
injected with AC-GFP, EGFP fluorescence was observed through-
out the optic nerve (Fig 5b). However no fluorescence was detected
in brain sections following subretinal injection and this expression
was not observed in TFA-GFP injected eyes (data not shown).
To avoid retinal autofluorescence and specifically determine the
retinal cell types expressing EGFP after subretinal injection, we
performed immunofluorescence microscopy using a Cy-3 conju-
gated antibody against EGFP (Fig 6). EGFP immunoreactivity was
Figure 1. Differential shape of the trifluoroacetate (TFA) and acetate
(AC) nanoparticles as visualized by electron microscopy. During
compaction of the EGFP expression plasmid, the presence of TFA as the
lysine counterion produces ellipsoidal nanoparticles with a minor
diameter ,18 nm whereas acetate produces rods with a minor
diameter ,8 nm. Scale bar, 100 nM.
doi:10.1371/journal.pone.0000038.g001
Figure 2. Ocular expression levels of EGFP mRNA after intravitreal
injection. At 2 days post-intravitreal injection of 0.6 mg of compacted
DNA, the lens, pigment epithelium/choroid/sclera (PECS), and retina
were isolated. qRT-PCR was used to assess EGFP mRNA levels and
normalized to the neuronal housekeeping gene HPRT. Both the AC-GFP
and TFA-GFP nanoparticles produced substantial expression of EGFP in
the lens as compared to the naked plasmid control. In the PECS (A) and
retina (B), both nanoparticles produced EGFP mRNA at levels several
fold higher than naked plasmid. No expression of EGFP was detected in
any of the mock-injected samples.
doi:10.1371/journal.pone.0000038.g002
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of photoreceptors and RPE cells in the naked plasmid injected
samples. However, strong labeling was observed in the AC-GFP
injected eyes throughout the entire photoreceptor population.
Furthermore, labeling was also present in the RPE and inner
nuclear layer (INL). No migration of immune cells into the eye was
observed in any sections examined (data not shown). To further
determine whether exposure to nanoparticles was toxic to retinal
cells, we performed subretinal injections of saline, naked plasmid,
AC-GFP, or TFA-GFP and assessed retinal function by electro-
retinography (ERG) at 7 and 30 days post-injection (Fig 7). If these
nanoparticles induced toxicity, the resultant loss of cell viability
and number should be apparent when retinal function is assessed.
At 7 days post-injection, a reduction in scotopic a- and b-wave as
well as in photopic b-wave amplitudes was detected in all samples
when compared to uninjected WT mice (Fig 7a). This decrease in
retinal function following subretinal injection is consistent with our
previous observation and reflects the diminished photransduction
potential as a consequence of retinal detachment from the
RPE[39]. However, among the injected samples, no significant
difference was observed in ERG amplitudes between saline-,
naked plasmid-, AC-GFP-, and TFA-GFP-injected samples. By 30
days post-injection, no significant difference in scotopic and
photopic amplitudes was detected between WT and any of the
injected eyes (Fig 7b). This demonstrates that the compacted
DNA nanoparticles have no deleterious effect on the function of
photoreceptors or their associated neurons and further confirms
the lack of an infiltrating immune response as this would have
caused a loss of retinal cells followed by reduction in ERG
amplitudes.
As different genetic deficits or diseases could require differential
levels of gene transfer, we investigated whether nanoparticle
transfection could be titrated based upon the dose of DNA
delivered. We performed subretinal injection of multiple dilutions
of the AC-GFP nanoparticles and assessed retinal expression by
qRT-PCR (Fig 8). A distinct correlation was observed between the
dose of the nanoparticles injected and the level of retinal transgene
expression. We also assessed mRNA levels of several photorecep-
tor genes that are mutated in human retinal dystrophies to put the
levels of EGFP expression into context. We observed that several
of the doses tested gave levels of mRNA expression nearly equal to
that of the photoreceptor genes examined. These data demon-
strate that the dose of compacted DNA nanoparticles can be
Figure 3. EGFP localization in ocular tissues following intravitreal
injection. Direct fluorescence microscopy was utilized to localize EGFP
expression in ocular tissues at 2-days post-injection of 0.6 mgo f
compacted DNA. (A) Retinal autofluorescence was present in the outer
segment of all samples including mock- and naked plasmid-injected
eyes, however EGFP fluorescence was detected in the GCL of both the
AC-GFP and TFA-GFP injected eyes. (B) Upon examination at higher
magnification, EGFP expression was confined to the GCL in the AC-GFP-
injected eyes, and present in the GCL and IPL of TFA-GFP-injected eyes.
(C) Expression of EGFP was also detected in the cornea, trabecular
meshwork, and lens following intravitreal injection of both TFA and AC
nanoparticles (only AC shown). ‘‘FITC’’ channel imaging was performed
as described in the Methods Section. OS: Outer Segment; ONL: Outer
Nuclear Layer; INL: Inner Nuclear Layer; IPL: Inner Plexiform Layer; GCL:
Ganglion Cell Layer; CO: Cornea; TM: Trabecular Meshwork; LE: Lens.
Scale bars, 10 mM.
doi:10.1371/journal.pone.0000038.g003
Figure 4. Ocular expression levels of EGFP mRNA after subretinal
injection. At 2-days post-subretinal injection of 0.6 mg of compacted
DNA, the lens, PECS, and retina were isolated, and qRT-PCR was used to
assess EGFP mRNA levels. Both the AC-GFP and TFA-GFP nanoparticles
produced substantial expression in the PECS and retina. In both tissues,
the AC-GFP nanoparticle generated EGFP mRNA levels nearly 2-fold
higher than the TFA-GFP nanoparticle. EGFP expression was also
observed in the lens; however there was significant deviation between
samples, possibly reflecting the amount of nanoparticle reflux into the
vitreous because of back-pressure during syringe withdrawal following
some of the subretinal injection procedures.
doi:10.1371/journal.pone.0000038.g004
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even comparable to the level of endogenous rhodopsin mRNA.
DISCUSSION
Herein we have demonstrated that compacted DNA nanoparticles
represent a safe and feasible means of gene transfer to various cell
types of the eye. High levels of gene expression were documented
in the retina, RPE, RGC, INL, and lens and there was no
evidence of cellular infiltration or inflammation. We focused on
characterizing the effects of gene transfer at 2-days post-injection
as this was the peak of reporter gene expression we observed and
the CMV promoter used is known to be silenced as early as 1 to 2
days post-transfection [40–42]. Although the data here did not
examine longevity, other studies our laboratory using different
plasmid elements has resulted in an expression duration of several
months [43]. Another study demonstrated the efficacy and safety
of this methodology in human subjects [32]. This system therefore
provides a safe and effective strategy for gene therapy to correct
multiple ocular diseases.
Intravitreal injection of the two types of nanoparticles tested
drove strong expression of our reporter gene in the inner retina
and in ocular tissues near the vitreous. The levels of EGFP mRNA
in the lens were relatively equal between eyes receiving the AC-
GFP or TFA-GFP nanoparticle, however in the retina and PECS
a difference was detected between the two nanoparticles. The
TFA-GFP nanoparticle produced EGFP expression levels nearly
5-fold higher than the AC-GFP in the retina. Upon examination
of fluorescence from retinal sections, it appears that both
nanoparticles conferred expression in RGCs, but only the TFA-
GFP produced EGFP within the IPL, suggesting that these
particles were able to transfect some cells within the inner nuclear
layer. This difference in transfectivity may be explained by the
different shapes and sizes of the nanoparticles that are produced
by varying the counterion (AC or TFA) at the time of compaction
or by different receptor affinities for the two formulations. The
AC-GFP nanoparticles consist of rod-shaped structures whereas
the TFA-GFP nanoparticles are ellipsoidal in shape (Fig 1). These
formulations may have different diffusive properties in the ordered
structure of the retina. Additionally, these nanoparticle formula-
tions may have different affinities for the receptor that permits
cellular uptake [44,45]. Varying the counterion has been shown to
confer different transfection patterns between cell types. For
example, AC but not TFA nanoparticles can transfect striated
muscle cells in mice [31], an observation that correlates well with
our finding that AC-GFP, but not TFA-GFP, transfects extrao-
cular muscle fibers (Fig 5b).
Subretinal injection of both types of nanoparticles resulted in
substantial transfection of the retina and RPE. The TFA-GFP
nanoparticle drove strong expression in the RPE cell layer,
although it was not as proficient in promoting expression in the
photoreceptors. In contrast, the AC-GFP nanoparticle drove
strong levels of expression in the entire photoreceptor cell layer
and EGFP also was detected in the inner nuclear layer cells nearest
to the photoreceptors. Furthermore, the delivery of compacted
DNA nanoparticles did not produce a decrease in retinal function
as assessed by ERG analyses (Fig 7) and there was no evidence of
inflammation in histologic sections of the retina, demonstrating
that this methodology does not have any overtly damaging
consequences to retinal cells.
Taken together, our data suggest that this mode of gene
therapy is applicable for multiple forms of ocular diseases. As
intravitreal injection targets the tissues in the front of the eye, this
mode of therapy could be widely applicable for corneal diseases
such as cataracts and keratoconus. Expression of inflammatory
regulators and siRNA may also be effective modes of treating
infectious diseases affecting the cornea [46,47]. This route of
injection also was effective in transfecting retinal ganglion cells
whereas optic nerve cells were transfected following subretinal
injection. The latter finding indicates that AC nanoparticles can
be transported in a retrograde fashion to the cell nuclei of optic
nerve fibers in the lateral geniculate nucleus. Therefore, these
methodologies might be suitable for treating multiple optic nerve
diseases, including optic neuritis, Leber’s hereditary optic
neuropathy, and glaucoma [48,49]. Specifically, delivery of brain
derived neurotrophic factor (BDNF) had a protective effect in
animal models of glaucoma [50]. With the use of nanoparticle-
mediated gene transfer, it may be possible to have retinal
ganglion and optic nerve cells produce substantial levels of
BDNF to promote their own sustainability during the stress from
intraocular pressure that is observed in glaucoma. For other
types of optic nerve injuries, the production of oncomodulin by
DNA nanoparticles could be a practical approach for regenerat-
ing damaged axons [51]. Also, a recent study demonstrated that
Figure 5. EGFP localization in ocular tissues following subretinal
injection. Direct fluorescence microscopy was utilized to localize EGFP
expression in ocular tissues at 2-days post-injection of 0.6 mgo f
compacted DNA. (A) EGFP fluorescence was detected in the ONL and
RPE of eyes injected with the AC-GFP and TFA-GFP nanoparticles,
respectively. (B) EGFP was also detected within the optic nerve
(asterisks) and the extraocular muscles following injection of the AC-
GFP nanoparticle. Scale bars, 10 mM.
doi:10.1371/journal.pone.0000038.g005
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ganglion cells was capable of restoring visual function in mice
lacking photoreceptors [52]. Consequently, intravitreal injection
to deliver this gene to RGCs may be a feasible approach for
a multitude of retinal degenerative disorders. Furthermore,
previous studies using polystyrene nanospheres described the
vitreous as a barrier to gene transfer [53], however the
specialized compaction procedure utilized for the DNA nano-
particles used here produced a significantly smaller particle that
seemed to be freely diffusible through the vitreous.
Figure 6. EGFP immunoreactivity following subretinal injection. To eliminate any artifacts due to retinal autofluorescence, immunohistochemistry
was performed with a Cy-3-anti-GFP antibody on paraffin-embedded ocular sections from eyes taken at 2-days post-injection of 0.6 mg of compacted
DNA. An absence of or minimal EGFP immunoreactivity was found in the mock-injected and naked plasmid-injected eyes, respectively. Examination
of sections from eyes injected with the AC-GFP nanoparticle revealed high-level EGFP immunoreactivity in nearly all of the cells in the ONL. Lower
levels of EGFP were also detected within the upper half of the INL. Scale bar, 10 mM.
doi:10.1371/journal.pone.0000038.g006
Figure 7. Assessment of retinal function following subretinal injection. ERG analyses were performed in adult Balb/c mice (n=4) after 7 and 30
days following subretinal delivery of 1 uL saline, naked plasmid, AC-GFP, or TFA-GFP and compared to uninjected controls (UN). To assess rod
photoreceptor function and signal transmission scotopic ERG was performed on dark-adapted mice and photopic ERG was performed light-adapted
mice to assess cone photoreceptor function. (A) At 7 days post-injection, a significant decrease from WT amplitudes was observed in all injected eyes
(p,0.05) as an immediate consequence of the injection procedure and subsequent retinal detachment, however there was no significant difference
among any of the experimental groups (p.0.05) in the scotopic and photopic amplitudes. (B) By 30 days post-injection, no significant difference in
scotopic and photopic amplitudes was observed between WT and injected groups (p.0.05), demonstrating the lack of toxicity associated with
nanoparticle-transfection in photoreceptors. Significance was determined with ANOVA and Bonferroni’s pair-wise comparison test.
doi:10.1371/journal.pone.0000038.g007
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photoreceptor and RPE cells, demonstrating a significant utility
for this non-viral system in rescuing multiple forms of retinal
disease. As this system is capable of delivering large DNA cassettes,
it would be possible to deliver the entire gene structure in some
cases. For many inherited retinal diseases such as retinitis
pigmentosa and Stargardt’s disease, the disease pathogenesis
arising from genetic mutations is understood and gene therapy
strategies have already been developed [4,11,15,54]. The de-
velopment of other complex diseases such as age related macular
degeneration (AMD) is not completely understood, although
genetic mutations have been identified as risk factors and
supplementation of the wild-type genes may be a treatment option
[55–58]. Current therapies available for the treatment of the
‘‘wet’’ form of AMD involve the use of small molecules to block
the activity of vascular endothelial growth factor, but entail
recurring injections to maintain this inhibitory effect [59–61]. The
use of gene transfer to deliver an expression cassette to
photoreceptors and RPE cells that produces a similar inhibitory
molecule may be a less invasive strategy as it could produce a more
sustained effect. This nanoparticle system shows tremendous
promise as the basis for developing strategies to treat various
diseases of the eye.
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